ClinicalTrials.gg
RecruitingNCT06337318Updated Nov 18, 2026

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

A Phase 3 interventional study of Biospecimen Collection and Computed Tomography in Classic Follicular Lymphoma and Follicular Lymphoma With Unusual Cytological Features, sponsored by National Cancer Institute (NCI). Recruiting at 289 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Nov 18, 2026Site recruiting status changed7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing mosunetuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 3 of them phase 3. mosunetuzumab · Lymphoma, Follicular.

Planned enrollment
2nd of 17
600 · median 42
Started
2024
with 4 others
Phase 3
3 of 17
1 open now
Primary completion
2032-03
later than 13 of 14 live
Registered
12th of 17
by date
Lead sponsor
1 of 17
National Cancer Institute (NCI)

Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2024, is one of 3 in phase 3, reaches primary completion later than 13 of the 14 other live ones, and was the 12th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 17 studies testing mosunetuzumab in Lymphoma, Follicular are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About mosunetuzumab

mosunetuzumab: first FDA approval 2022 (LUNSUMIO VELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing mosunetuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare the 3-year milestone progression free survival (PFS) probabilities in participants with previously untreated, low tumor burden follicular lymphoma randomized to the rituximab arm versus the mosunetuzumab arm.

II. To compare progression free survival (PFS) in participants with previously untreated, low tumor burden follicular lymphoma randomized to the rituximab arm versus the mosunetuzumab arm.

SECONDARY OBJECTIVES:

I. To compare overall survival (OS) between participants randomized to rituximab versus mosunetuzumab.

II. To compare overall response rates at the Week 40 assessment between participants randomized to rituximab versus mosunetuzumab.

III. To compare event free survival (EFS) between participants randomized to rituximab versus mosunetuzumab.

IV. To compare the frequency and severity of toxicities between participants randomized to rituximab versus mosunetuzumab.

V. To compare the restricted chance of longer PFS (2-6 years) between participants randomized to rituximab versus mosunetuzumab.

BANKING OBJECTIVE:

I. To bank specimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive rituximab intravenously (IV) on day 1 of cycle 1 and receive rituximab and hyaluronidase subcutaneously (SC) on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan and/or positron emission tomography (PET)/CT and blood sample collection on study and during follow up.

ARM II: Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.

After completion of study treatment, patients are followed up every 6 months for 5 years and then yearly for a total of 10 years.

03

Conditions studied

  • Classic Follicular Lymphoma
  • Follicular Lymphoma With Unusual Cytological Features
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participants must have a confirmed diagnosis of classic follicular lymphoma (cFL). cFL was previously categorized as grade 1-3A per World Health Organization (WHO)-HAEM4R, but grading of classic follicular lymphoma (FL) is no longer mandatory.

    • NOTE: Participants with follicular lymphoma with uncommon features (uFL) are eligible, including FL with diffuse growth pattern (dFL). Diagnosis is as per local pathology. Lymphoma fluorescence in situ hybridization (FISH) is not required. Molecular testing is not required.
  • Participants must not have follicular lymphoma with "blastoid" or "large centrocyte" cytological features, or follicular large B-cell lymphoma (FLBL) (previously categorized as follicular lymphoma grade 3B)
  • Participants must have low-tumor burden follicular lymphoma defined as:

    • Nodal or extra-nodal tumor mass with diameter less than 7 cm in its greater diameter
    • Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.
    • Absence of B symptoms which may include unexplained fever, drenching sweats, unintentional weight loss (more than 10% of body weight)
    • No symptomatic splenomegaly
    • No compression syndrome (ureteral, orbital, gastrointestinal)
    • No pleural or peritoneal serous effusion related to follicular lymphoma Participants must have Ann Arbor stage II, III, or IV follicular lymphoma. Participants with stage I disease may be included if they do not wish to undergo radiation or are not candidates for radiation
  • Participants must either be experiencing distress due to their disease or would prefer active management of their disease rather than a watch and wait approach
  • Participants must have staging imaging performed within 49 days prior to registration, as follows. PET-CT baseline scans are preferred. If a baseline PET-CT scan cannot be obtained, CT scans of the chest, abdomen, and pelvis, along with a bone marrow , are acceptable. If CT scans are used for staging at baseline, a CT scan of the neck is recommended. All measurable dominant lesions must be assessed within 49 days prior to registration. Tests to assess non- must be performed within 49 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form.

    • NOTE: if the initial evaluation is insufficient to detect measurable disease, treating investigators may obtain a CT scan with contrast
  • Participants must have bi-dimensionally measurable disease (at least one lesion with longest diameter > 1.5 cm)
  • Participants must not have had prior systemic therapy for follicular lymphoma. Radiation therapy for a previous diagnosis of early-stage follicular lymphoma is allowed
  • Participant must be ≥ 18 years of age at the time of registration
  • Participant must have Zubrod performance status of 0-2
  • Participant must have a complete medical history and physical exam within 28 days prior to registration
  • Leukocytes ≥ 3 x 10\^3/uL (within 28 days prior to registration)
  • > 9.0 g/dL (within 28 days prior to registration)
  • ≥ 1.5 x 10\^3/uL (within 28 days prior to registration)
  • ≥ 100 x 10\^3/uL (within 28 days prior to registration)
  • Total ≤ 2 x institutional (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN (within 28 days prior to registration)
  • (AST)/alanine aminotransferase (ALT) ≤ 3 × institutional ULN (within 28 days prior to registration)
  • Participants must have a calculated ≥ 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been collected and processed within 28 days prior to registration
  • Participants must not have an active or uncontrolled infection before initiation of study treatment in the opinion of the treating investigators
  • Participants must not have uncontrolled diabetes within 14 days prior to registration in the opinion of the treating investigators
  • Participants must not have uncontrolled blood pressure and hypertension within 14 days prior to registration in the opinion of the treating investigators
  • Participants with known (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration
  • Participants with evidence of chronic virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to registration, if indicated. Participants with a positive total hepatitis (Hep) B core antibody and negative hepatitis B virus surface antigen (HBsAg) at screening are at high risk for reactivation and should receive prophylactic antivirals (e.g., entecavir) before and throughout the treatment
  • Participants must not have disease requiring systemic therapy
  • Participants must not have had undergone organ transplants requiring ongoing systemic immunosuppressive therapy
  • Participants with a history of virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to registration, if indicated
  • Participants must not have known chronic active Epstein Barr Virus infection (CAEBV); testing in asymptomatic participants is not required
  • Participants must not have a positive test result for COVID-19 within seven (7) days prior to registration
  • Participants must not have a prior or concurrent whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the regimen
  • Participants must not have a history of confirmed progressive multifocal leukoencephalopathy (PML)
  • Participants must not have received stem cell transplantation
  • Participants must not have a history of macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH)
  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the Functional Classification. Participant must not have significant cardiovascular disease such as class III or IV cardiac disease, myocardial infarction within 6 months prior to registration. Participants with unstable arrhythmias, or unstable angina, should be excluded
  • Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of must have agreed to use an effective method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
  • Participants registered by participating United States (U.S.) sites must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
  • NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

    • Participants must be informed of the investigational nature of this study and must sign and give in accordance with institutional and federal guidelines
    • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Arm I (Rituximab, rituximab and hyaluronidase)

    Patients receive rituximab IV on day 1 of cycle 1 and receive rituximab and hyaluronidase SC on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Positron Emission Tomography · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human

  • Experimental
    Arm II (Mosunetuzumab)

    Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Biological: Mosunetuzumab · Procedure: Positron Emission Tomography

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT and/or PET/CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • BiologicalMosunetuzumab

    Given SC

    Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816

  • ProcedurePositron Emission Tomography

    Undergo PET/CT scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • BiologicalRituximab

    Given IV

    Also known as: ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima

  • BiologicalRituximab and Hyaluronidase Human

    Drug page: Rituximab and Hyaluronidase HumanStudies of Rituximab and Hyaluronidase HumanRituximab and Hyaluronidase Human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC

    Also known as: Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human

06

What researchers measure

Primary outcomes

  1. 3-year milestone progression free survival (PFS)

    Time frame: From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 3 years

  2. PFS

    Time frame: From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 10 years

Secondary outcomes

  1. Overall survival

    Will be estimated using the method of Kaplan-Meier and compared between treatment arms using cox regression model.

    Time frame: Up to 10 years

  2. Overall response rate

    Time frame: At week 40

  3. Event free survival (EFS)

    Will be estimated using the method of Kaplan-Meier and compared between treatment arms using cox regression model.

    Time frame: From date of registration to date of first occurrence of EFS event, up to 10 years

  4. Incidence of adverse events

    Will be evaluated using the Common Terminology Criteria for Adverse Events version 5 items.

    Time frame: Up to end of treatment

  5. Restricted chance of longer PFS

    Time frame: Up to 10 years

Other outcomes

  1. PFS hazard ratios

    Will be estimated for subgroups defined by sex, race and ethnicity with the corresponding 95% confidence intervals.

    Time frame: Up to 10 years

07

Study locations

264 of 289 sites recruiting

Showing the first 100 of 289 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

17 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2032, 89 months after the start.

Of 35 non-industry phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 116. This study's planned 89 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2024
First posted
Mar 29, 2024
StartActual
Oct 23, 2024
Primary completionEst.
Mar 31, 2032
CompletionEst.
Mar 31, 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 1 site removed. 8 sites changed recruiting status (5 now suspended, 2 now recruiting, …)
Show 8 sites
  • OptumCare Cancer Care at Charleston · Las Vegas, United StatesRecruiting→Suspended
  • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesRecruiting→Suspended
  • Henry Ford Health Providence Southfield Hospital · Southfield, United StatesRecruiting→Suspended
  • Asplundh Cancer Pavilion · Willow Grove, United StatesRecruiting→Suspended
  • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
  • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
  • MedStar Georgetown University Hospital · Washington D.C., United StatesRecruiting→Suspended
  • Veteran Administration Eastern Kansas Healthcare · Leavenworth, United StatesSuspended→Active, not recruiting
Show 7 added (7 United States)
  • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
  • OSF Saint Francis Hospital and Medical Group · Escanaba, United States
  • Schoolcraft Memorial Hospital · Manistique, United States
  • Renown Regional Medical Center · Reno, United States
  • Marshfield Medical Center-Rice Lake · Rice Lake, United States
  • Minnesota Oncology - Edina · Edina, United States
  • PeaceHealth Saint Joseph Medical Center · Bellingham, United States
Show 1 removed
  • West Virginia University Charleston Division · Charleston, United States
across 16 updates, Oct 1, 2026 – Nov 18, 2026
Site contacts
Changed at 17 sites. See the sites
Show 17 sites
  • West Virginia University Charleston Division · Charleston, United StatesContact none listed→C•••@vandaliahealth.org
  • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • OptumCare Cancer Care at Charleston · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
  • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
  • Novant Health Presbyterian Medical Center · Charlotte, United StatesContact added k•••@novanthealth.org · •••6360Contact added (no phone or email listed)
  • Novant Health Cancer Institute - Mooresville · Mooresville, United StatesContact added k•••@novanthealth.org · •••6360Contact added (no phone or email listed)
  • Henry Ford Health Providence Southfield Hospital · Southfield, United StatesContact removed k•••@hfhs.org · •••5332Contact removed (no phone or email listed)
  • Novant Health Forsyth Medical Center · Winston-Salem, United StatesContact added p•••@novanthealth.org · •••8335Contact added (no phone or email listed)
  • Thomas Jefferson University Hospital · Philadelphia, United StatesContact person changed (no phone or email listed)
  • Asplundh Cancer Pavilion · Willow Grove, United StatesContact removed O•••@jefferson.edu · •••9151Contact removed (no phone or email listed)
  • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact added c•••@karmanos.org · •••6266Contact added (no phone or email listed)
  • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
  • University Health Truman Medical Center · Kansas City, United StatesContact added •••4375Contact added (no phone or email listed)
  • MedStar Georgetown University Hospital · Washington D.C., United StatesContact removed •••2223Contact removed (no phone or email listed)
across 12 updates, Sep 29, 2026 – Nov 9, 2026
Show all 17 updates
  1. Nov 18, 2026
    1 site added
    Show site
    • PeaceHealth Saint Joseph Medical Center · Bellingham, United States
  2. Nov 9, 2026
    Asplundh Cancer Pavilion is now Suspended
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Thomas Jefferson University Hospital · Philadelphia, United StatesContact person changed (no phone or email listed)
    • Asplundh Cancer Pavilion · Willow Grove, United StatesContact removed O•••@jefferson.edu · •••9151Contact removed (no phone or email listed)
  3. Nov 3, 2026
    Veteran Administration Eastern Kansas Healthcare is now Active, not recruiting
  4. Oct 28, 2026
    MedStar Georgetown University Hospital is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • MedStar Georgetown University Hospital · Washington D.C., United StatesContact removed •••2223Contact removed (no phone or email listed)
  5. Oct 26, 2026
    1 site added
    Show site
    • Minnesota Oncology - Edina · Edina, United States
  6. Oct 23, 2026
    1 site added. University Health Truman Medical Center is now Recruiting
    Show site
    • Marshfield Medical Center-Rice Lake · Rice Lake, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University Health Truman Medical Center · Kansas City, United StatesContact added •••4375Contact added (no phone or email listed)
  7. Oct 21, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesSuspended→Recruiting
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact added c•••@karmanos.org · •••6266Contact added (no phone or email listed)
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
  8. Oct 20, 2026
    3 sites changed recruiting status (3 now suspended)
    Show 3 sites
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesRecruiting→Suspended
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesRecruiting→Suspended
    • University Health Truman Medical Center · Kansas City, United StatesRecruiting→Suspended
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact removed c•••@karmanos.org · •••6266Contact removed (no phone or email listed)
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact removed c•••@karmanos.org · •••9790Contact removed (no phone or email listed)
    • University Health Truman Medical Center · Kansas City, United StatesContact removed •••4375Contact removed (no phone or email listed)
  9. Oct 14, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
    • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
    • Providence Portland Medical Center · Portland, United StatesSuspended→Recruiting
    • Providence Saint Vincent Medical Center · Portland, United StatesSuspended→Recruiting
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  10. Oct 13, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Novant Health Forsyth Medical Center · Winston-Salem, United StatesSuspended→Recruiting
    • Asplundh Cancer Pavilion · Willow Grove, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Novant Health Forsyth Medical Center · Winston-Salem, United StatesContact added p•••@novanthealth.org · •••8335Contact added (no phone or email listed)
    • Asplundh Cancer Pavilion · Willow Grove, United StatesContact added O•••@jefferson.edu · •••9151Contact added (no phone or email listed)
  11. Oct 9, 2026
    1 site added. Asplundh Cancer Pavilion is now Suspended
    Show site
    • Renown Regional Medical Center · Reno, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Thomas Jefferson University Hospital · Philadelphia, United StatesContact person changed (no phone or email listed)
    • Asplundh Cancer Pavilion · Willow Grove, United StatesContact removed O•••@jefferson.edu · •••9151Contact removed (no phone or email listed)
  12. Oct 8, 2026
    4 sites changed recruiting status (2 now suspended, 2 now recruiting)
    Show 4 sites
    • Henry Ford Health Providence Southfield Hospital · Southfield, United StatesRecruiting→Suspended
    • Novant Health Presbyterian Medical Center · Charlotte, United StatesSuspended→Recruiting
    • Novant Health Cancer Institute - Mooresville · Mooresville, United StatesSuspended→Recruiting
    • Novant Health Forsyth Medical Center · Winston-Salem, United StatesRecruiting→Suspended
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Henry Ford Health Providence Southfield Hospital · Southfield, United StatesContact removed k•••@hfhs.org · •••5332Contact removed (no phone or email listed)
    • Novant Health Presbyterian Medical Center · Charlotte, United StatesContact added k•••@novanthealth.org · •••6360Contact added (no phone or email listed)
    • Novant Health Cancer Institute - Mooresville · Mooresville, United StatesContact added k•••@novanthealth.org · •••6360Contact added (no phone or email listed)
    • Novant Health Forsyth Medical Center · Winston-Salem, United StatesContact removed p•••@novanthealth.org · •••8335Contact removed (no phone or email listed)
  13. Oct 7, 2026
    4 sites changed recruiting status (4 now suspended)
    Show 4 sites
    • OptumCare Cancer Care at Charleston · Las Vegas, United StatesRecruiting→Suspended
    • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesRecruiting→Suspended
    • Novant Health Presbyterian Medical Center · Charlotte, United StatesRecruiting→Suspended
    • Novant Health Cancer Institute - Mooresville · Mooresville, United StatesRecruiting→Suspended
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • OptumCare Cancer Care at Charleston · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
    • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
    • Novant Health Presbyterian Medical Center · Charlotte, United StatesContact removed k•••@novanthealth.org · •••6360Contact removed (no phone or email listed)
    • Novant Health Cancer Institute - Mooresville · Mooresville, United StatesContact removed k•••@novanthealth.org · •••6360Contact removed (no phone or email listed)
  14. Oct 6, 2026
    2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Providence Portland Medical Center · Portland, United StatesRecruiting→Suspended
    • Providence Saint Vincent Medical Center · Portland, United StatesRecruiting→Suspended
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Providence Portland Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  15. Oct 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • OSF Saint Francis Hospital and Medical Group · Escanaba, United States
    • Schoolcraft Memorial Hospital · Manistique, United States
  16. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
    Show 1 removed
    • West Virginia University Charleston Division · Charleston, United States
  17. Sep 29, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • West Virginia University Charleston Division · Charleston, United StatesContact none listed→C•••@vandaliahealth.org

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06337318
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Oct 23, 2024
Primary completion
Mar 31, 2032 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

Nilanjan Ghosh
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mosunetuzumab · Rituximab · Rituximab and Hyaluronidase Human

Start the discussion